| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.036 | 0.6 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |